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Two of the main research priorities in the United States are cancer and neurodegenerative
diseases, which are attributed to abnormal patterns of cellular behavior. MicroRNAs
(miRNA) have been implicated as regulators of cellular metabolism, and thus are an active
topic of investigation in both disease areas. There is presently a more extensive body
of work on the role of miRNAs in cancer compared to neurodegenerative diseases, and
therefore it may be useful to examine whether there is any concordance between the
functional roles of miRNAs in these diseases. As a case study, the roles of miRNAs in
Alzheimer’s disease (AD) and their functions in various cancers will be compared. A number
of miRNA expression patterns are altered in individuals with AD compared with healthy
older adults. Among these, some have also been shown to correlatewith neuropathological
changes including plaque and tangle accumulation, as well as expression levels of other
molecules known to be involved in disease pathology. Importantly, these miRNAs have
also been shown to have differential expression and or functional roles in various types
of cancer. To examine possible intersections between miRNA functions in cancer and AD,
we review the current literature on these miRNAs in cancer and AD, focusing on their
roles in known biological pathways. We propose a pathway-driven model in which some
molecular processes show an inverse relationship between cancer and neurodegenerative
disease (e.g., proliferation and apoptosis) whereas others are more parallel in their activity
(e.g., immune activation and inﬂammation). A critical review of these and other molecular
mechanisms in cancer may shed light on the pathophysiology of AD, and highlight
key areas for future research. Conclusions from this work may be extended to other
neurodegenerative diseases for which some molecular pathways have been identiﬁed but
which have not yet been extensively researched for miRNA involvement.
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INTRODUCTION
Cancer and neurodegenerative disease have become prominent
areas of medical research in the United States, as these diseases
afﬂict millions of Americans each year. Since age is a major risk
factor for each disease area, our aging population makes progress
in treatment a high priority (Qiu et al., 2009; Borgesius et al.,
2011; Jeppesen et al., 2011; Howlader et al., 2012). Fundamen-
tal hallmarks of cancer include uncontrolled proliferation and
disruption of apoptosis; conversely neurodegeneration is associ-
ated with increased cellular death (Hanahan and Weinberg, 2000;
Leuner et al., 2012). Therefore, both diseases may potentially
result from differential regulation of the same cellular pathways.
Supporting this hypothesis, negative epidemiological correlations
have been demonstrated between cancer and neurodegenerative
diseases including Down’s syndrome, Parkinson’s disease (PD),
Alzheimer’s disease (AD), schizophrenia, and multiple sclerosis
(Tabares-Seisdedos et al., 2011). Interestingly, to date, although
the rest of these neurodegenerative diseases appear to be associ-
ated with either increased or decreased comorbidity depending
on the type of cancer, AD has been associated with a decreased
co-occurrence of all types of cancer. A recent large-scale report
indicated a signiﬁcant negative correlation of cancer and AD in
the Framingham Heart Study (Driver et al., 2012). In a longitu-
dinal study, patients with AD also had a lower risk of developing
cancer after adjusting for demographic factors (Roe et al., 2005).
Further, Caucasian participants in another prospective study dis-
played a negative association between AD incidence and cancer
risk (Roe et al., 2010).
MicroRNAs (miRNAs) comprise onemajorpost-transcriptional
regulatorymechanism that has been implicated in a variety of can-
cers and neurodegenerative diseases (Zhang et al., 2007; Bushati
and Cohen, 2008;Wu et al., 2008; Garzon et al., 2009a; Lau and de
Strooper, 2010; Sonntag, 2010). As illustrated in Figure 1, miRNA
is generated as a long precursor sequence in the nucleus, where
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FIGURE 1 | MiRNA generation and function.The nuclear transcript
pri-miRNA is several kilobases in length; this transcript is cleaved by the
microprocessor complex (DCGR8 and Drosha), which yields a short (∼65
nucleotide) stem-loop pre-miRNA. This is transported out of the nucleus by
Exportin 5 (Exp5) to the RNA-induced silencing complex (RISC) and cleaved
by DICER1 (targeting the hairpin loop), generating a ∼22 nucleotide miRNA
duplex; one-strand is degraded, and the remaining strand is loaded into
human immunodeﬁciency virus-1 transactivating response RNA-binding
protein (TRBP)-recruited EIF2C2, also known as Argonaute 2, which then
inhibits translation of target messenger RNAs (mRNAs; Bartel, 2004;
Gregory et al., 2004, 2005; Chendrimada et al., 2005; Maniataki and
Mourelatos, 2005; Kim et al., 2009; Rusca and Monticelli, 2011).
it is cleaved to form a shorter stem-loop precursor, transported
to the cytoplasm, and further processed in the RNA-induced
silencing complex (RISC) by the ribonuclease DICER1 into a
very short (∼22 nucleotide) double-strand sequence; this is then
unwound and one-strand is loaded onto EIF2C2, which con-
sequently inhibits translation or results in cleavage of target
messenger RNAs (mRNAs; Bartel, 2004; Gregory et al., 2004, 2005;
Chendrimada et al., 2005; Maniataki and Mourelatos, 2005; Kim
et al., 2009; Rusca and Monticelli, 2011).
The same miRNAs can be important to both types of disease; a
few examples includemiR-34b/c down-regulation in PD and small
cell lung cancer, up-regulation of miR-206 as a protective effect
against disease progression in a mouse model of amyotrophic lat-
eral sclerosis andmiR-206 down-regulation in laryngeal squamous
cell carcinoma, and miR-132 down-regulation in frontotemporal
dementia andmethylation in prostate cancer (Williams et al., 2009;
Minones-Moyano et al., 2011; Zhang et al., 2011b; Chen-Plotkin
et al., 2012; Formosa et al., 2012; Tanaka et al., 2012). To date, there
has been a focus onmiRNAs in cancer. Although the roles of miR-
NAs in neurodegenerative diseases have not been as thoroughly
investigated, these are currently under increasing scrutiny (Gas-
con and Gao, 2012). Given the plethora of information on cancer
regulatory mechanisms including miRNA, as well as the possible
involvement of some of the same miRNAs in cancer and neu-
rodegeneration, consideration of the roles of miRNA functions in
cancer might help elucidate corresponding or opposing functions
in neurodegenerative disease. A more comprehensive review of
the roles of miRNAs in cancer and neurodegeneration might yield
insights into the underlying pathways involved in these diseases.
The full spectrum of roles of miRNAs in different types of can-
cer and neurodegenerative diseases is a rich topic but beyond the
scope of this targeted review; we decided to focus our analysis
on select miRNAs implicated in both AD and cancer. AD pathol-
ogy is characterized by an accumulation of extracellular amyloid
plaques composed of amyloid-beta peptide fragment (Aβ) and
intracellular neuroﬁbrillary tangles composed of hyperphospho-
rylated protein tau, as well as neuronal loss in the hippocampus,
temporal, and frontal lobes, increased inﬂammation, and oxida-
tive stress (Glenner and Wong, 1984; Grundke-Iqbal et al., 1986;
Kosik et al., 1986; Small and Duff, 2008; Gustaw-Rothenberg et al.,
2010; Pavlides et al., 2010; Mohsenzadegan and Mirshaﬁey, 2012).
We will review a number of studies linking miRNAs with differen-
tial expression and pathology in AD such as deposition of amyloid
plaques and neuroﬁbrillary tangles, as well as more speciﬁc path-
way interactions and regulatory functions of the amyloid pathway,
including regulation of amyloid protein precursor (APP) andbeta-
site APP cleaving enzyme 1 (BACE1 or β-secretase), a protease that
cleaves APP to generate Aβ. The larger form of Aβ peptide con-
taining 42 amino acid residues (Aβ42) mostly aggregates to form
the previously mentioned amyloid plaques (see Figure 2).
We will focus on eight miRNAs (miR-9, -29a/b, -101, -107,
-125b, -146a, -153, and -195) with differential expression in AD,
evidence of correlation with disease pathology, and evidence of
speciﬁc functional interactions, in order to investigate whether
the large body of cancer research on these molecules may shed
additional light on their function in AD, and whether it is also
possible to use existing knowledge of these miRNAs in AD to
further elucidate their functions in cancer. Serving as a case study
of the potential utility of this type of cross-disease comparison,
we suggest that miRNA research in cancer may lead to hypotheses
for novel roles of these miRNAs in AD, and highlight important
directions for future research.
We expect to observe miRNA involvement in cancer and AD
in pathways that may be contributing to both pathologies, as
well as activity in disease-speciﬁc pathways, and anticipate that
the differential expression and or regulation of these miRNAs
FIGURE 2 | MicroRNA involvement in the amyloid pathway appears to
contribute to AD. BACE1 mRNA expression appears to be redundantly
regulated by multiple miRNAs (including predicted miR-9, not shown); APP
mRNA expression is also regulated by miRNA. More miRNA binding sites
have been bioinformatically predicted for both mRNAs, indicating that this
regulatory mechanism is most likely very tightly regulated (Schonrock et al.,
2012). Solid lines indicate known interactions; dashed lines indicate
measured correlations.
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may contribute to the differences in disease pathology. In addi-
tion to the aforementioned proliferative/anti-apoptotic pathway,
we expect to observe miRNAs involved in invasion, metastasis,
inﬂammation, oxidative stress, and angiogenesis in cancer; since
many of these pathways have also been implicated in neurode-
generation, we expect that these miRNAs will also be implicated
in the same or related pathways in AD (Vagnucci and Li, 2003;
Lukiw, 2004; Segal et al., 2004, 2005; Rojo et al., 2008; Maccioni
et al., 2009; Streit et al., 2009; Tabares-Seisdedos et al., 2011; Cole
and Sood, 2012; Vadnal et al., 2012).
For some pathways, including proliferation and pro-survival
mechanisms, we expect to ﬁnd evidence of inverse relationships
(Driver and Lu, 2010; Driver et al., 2012; Hedskog et al., 2012);
however, for inﬂammation, oxidative stress, and angiogenesis it is
reasonable to expect similar activity since these are known factors
in both areas of pathology (Ono, 2008; Rojo et al., 2008; Mac-
cioni et al., 2009; Pavlides et al., 2010; Biron et al., 2011; Sethi et al.,
2012; Vendramini-Costa and Carvalho, 2012). Although there is
evidence that the neuro-immune and inﬂammatory pathways are
up-regulated in AD, in cancer there is evidence that immunity
can both suppress tumor growth and promote tumor progression,
a process referred to as “immunoediting” (Maccioni et al., 2009;
Schreiber et al., 2011; Vesely et al., 2011). Figure 3 summarizes the
documented and hypothesized roles of these pathways in cancer
and AD. A comparison of miRNA expression and activity may
yield more information on the contribution of these pathways to
disease initiation and progression.
miR-9
Three studies found that miR-9 was signiﬁcantly up-regulated in
the hippocampus and temporal lobe neocortex of AD brains com-
pared to normal aging brains, indicating that miR-9 may play
a pathological role in AD (Lukiw, 2007; Sethi and Lukiw, 2009;
Lukiw et al., 2012). Because these brain regions show extensive
pathology during the progression from health to AD (De Leon
et al., 1997; Jack et al., 1998; Desikan et al., 2010; Nath et al.,
2012; Spulber et al., 2012) up-regulation of miR-9 may play a
role in degeneration. However, other studies found miR-9 was
down-regulated in the hippocampus, anterior temporal cortex and
medial frontal gyrus in AD patients (Cogswell et al., 2008; Hebert
et al., 2008). Therefore, at present there is conﬂicting data regard-
ing the speciﬁc role of miR-9 in AD, and its expression pattern in
key cerebral regions and differences in sample characteristics and
methods may be a factor in directionality of changes. It should be
noted that miR-9 has a half-life of 30–60 min; the post-mortem
interval (PMI) for the three studies ﬁnding up-regulation of miR-
9 was 3 h or less, while the other two studies had PMIs of 3–10 and
24 h (Lukiw et al., 2012). It seems possible that this variability is
enough to explain the measurement discrepancies, in which case
miR-9 is up-regulated inADbrains, but decays at a rapid rate post-
mortem, causing it to appear down-regulated at later time points.
In terms of mechanism, miR-9 has been predicted to tar-
get the 3′ untranslated region (UTR) of BACE1, a key element
of the amyloid pathway, though to our knowledge there is cur-
rently no functional evidence of this interaction. If conﬁrmed,
this would support miR-9 down-regulation, presumably resulting
in increased BACE1 expression activity and increased Aβ42 pro-
duction (Hebert et al., 2008). Finally, there is some initial evidence
that miR-9 may be up-regulated in response to interleukin-1B
(IL-1β) and Aβ42 induced nuclear factor of kappa light polypep-
tide gene enhancer in B cells 1 (NF-κB), implying that this miRNA
may be involved in the AD inﬂammatory and oxidative stress
pathways (Lukiw, 2012). Brain-enriched miR-9 has also been
implicated in a wide variety of functions in different life stages and
organisms; overexpression in adult mouse neural progenitor cells
has been shown to facilitate neuronal differentiation, although
inhibitingmiR-9 does not inhibit differentiation (Krichevsky et al.,
2006; Yuva-Aydemir et al., 2011).
miR-9 is active in a variety of pathways, with both tumor
suppressive and oncogenic functions for different types of can-
cer. Down-regulation has been observed in metastatic melanoma
and head and neck squamous cell carcinoma (HNSCC; Liu et al.,
2012b; Minor et al., 2012), while up-regulation has been observed
in glioma, gastric cancer, biliary cancer,Hodgkin lymphoma (HL),
colorectal cancer (CRC), breast cancer, and cervical cancer (Li
et al., 2011b; Schraivogel et al., 2011; Shigehara et al., 2011; Inoue
et al., 2012; Krell et al., 2012; Leucci et al., 2012;Wilting et al., 2012;
Zhu et al., 2012b), indicating that this regulatory miRNA is likely
involved in multiple pathways, some of which are differentially
regulated in different cancer types.
FIGURE 3 | Molecular and cellular pathways important to AD and cancer:
increased levels of inflammation and oxidative stress have been
positively associated with cancer and AD. Angiogenesis is considered one
of the hallmarks of cancer, and has also been shown to be triggered by
amyloid in AD (Hanahan andWeinberg, 2000; Biron et al., 2011). Proliferation
and pro-survival pathways have been shown to be positively associated with
cancer and negatively associated with AD. Immunity has been shown to be
both positively and negatively correlated with cancer (“immunoediting”), in
addition to being positively correlated with AD. The amyloid pathway does not
appear to be involved in cancer pathways, so for the purposes of this review
is speciﬁc to AD. Blue lines indicate interactions found in AD research; orange
lines indicate interactions found in cancer research.
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There is functional evidence that this miRNA may act as a
tumor suppressor in some cancers. Cell proliferation was sig-
niﬁcantly inhibited in a HNSCC cell line by overexpression of
miR-9, indicating that it may be a negative regulator of this path-
way (Minor et al., 2012). miR-9 was also shown to down-regulate
proliferation and metastasis pathways in melanoma via the NF-
κB1 molecular pathway; it was shown to directly target the NF-κB
3′ UTR. Since NF-κB1 is known to be activated by inﬂammatory
and oxidative stress signals, this indicates that miR-9 may play an
important role in these pathways in cancer as well as AD (Pavlides
et al., 2010; Liu et al., 2012a,b). miR-9 is up-regulated by NF-κB
in AD, and down-regulates NF-κB in melanoma, suggesting that
there may be a negative feedback loop in AD or differential regula-
tion of this mechanism in AD and cancer. Additional research will
be required to determine which of these explanations is correct.
In contrast to the role of miR-9 in suppressing proliferation and
metastasis, and possible involvement in the NF-κB inﬂammatory
and oxidative stress pathways, other data indicate that miR-9 up-
regulates oncogenic pathways in cancer including proliferation,
metastasis, and invasion. An investigation of glioma found that
inhibition of miR-9 reduced tumor cell stemness and led to cel-
lular differentiation (Schraivogel et al., 2011). It was also shown
to increase cell motility, and overexpression down-regulated α-
catenin in CRC, indicating involvement in metastasis (Zhu et al.,
2012b). In breast cancer, miR-9 expression was up-regulated in
higher grade tumors, indicating that it may be involved in pro-
liferation and or metastasis (Krell et al., 2012). Involvement in
these pathways is also supported by research in cervical cancer,
where up-regulation of miR-9 was associated with increased cel-
lular viability, anchorage-independent growth, and migration in
vitro (Wilting et al., 2012). In an endometrial cancer cell line,miR-
9 was shown to signiﬁcantly reduce expression of Forkhead box
O1 (FOXO1), a transcription factor, while in another endome-
trial cancer cell line inhibition of this and several other miRNAs
resulted in re-expression of FOXO1, cell cycle arrest, and apop-
tosis (Myatt et al., 2010). Up-regulation of miR-9 in HL results
in repression of Hu antigen R [HuR; responsible for destabiliz-
ing messenger RNAs (mRNAs) to regulate gene expression] and
DICER1 (a major regulator of mRNA, see Figure 1), leading to
increased cytokine production by HL cells and attraction of nor-
mal inﬂammatory cells, indicating that miR-9 may be involved
in large-scale translational regulation as well as inﬂammation
pathways (Li et al., 2011b; Leucci et al., 2012).
There is conﬂicting evidence regarding the function and expres-
sion of this miRNA in AD and cancer, making interpretation of
its roles challenging. miR-9 has been found both up- and down-
regulated in affected tissue from AD brains and evidence suggests
it may play a role in BACE1 regulation. In cancer, there is evi-
dence that miR-9 can up-regulate oncogenic pathways including
proliferation, metastasis, and invasion. MiR-9 promotes stemness
and prevents differentiation in glioma, increases cell motility and
metastasis in CRC, and promotes proliferation and/or metasta-
sis in breast, endometrial, and cervical cancer, and is involved in
translational regulation and inﬂammation pathways in HL.
The evidence suggests that miR-9 may be important in AD, as
it has been shown to be differentially expressed in cerebral regions
which are signiﬁcantly associated with pathological progression,
yetmore research is needed to clarify themolecular causative func-
tions. Cancer research suggests a wide variety of possible functions
that could be tested for parallel associations inAD, from transcrip-
tional regulation, proliferation, inﬂammation, and high-impact
translational regulation, to differentiation. Of note,miR-9 appears
to have opposite inﬂuence on differentiation in neuronal develop-
ment and glioma. If miR-9 does up-regulate differentiation, as
suggested by the study of neuronal development, we might expect
this miRNA to be up-regulated in AD, resulting in a decrease in
neuronal precursors, and gradual neurodegeneration as a conse-
quence of reduced neuronal renewal. This is supported by the
reports of miR-9 up-regulation in the brains of AD patients.
miR-29
The majority of evidence suggests that miR-29 is down-regulated
inAD, though, similar tomiR-9, there is some conﬂicting evidence
regarding expression pattern. miR-29 was inversely correlated
with the density of amyloid plaques in adjacent tissue in brains
from individuals with AD (Wang et al., 2011). miR-29b was also
observed to be down-regulated in the parietal lobe cortex of
individuals with AD compared to age-matched controls (Nunez-
Iglesias et al., 2010). Additionally, loss of miR-29a/b in sporadic
AD was correlated with increased BACE1 protein expression, sup-
porting down-regulation of miR-29 in AD and also providing
evidence that miR-29 may be directly involved in the amyloid
pathway (Hebert et al., 2008). By contrast, in another study miR-
29a/b expression was increased in the medial frontal gyrus in AD
patients (Cogswell et al., 2008). This ﬁnding may reﬂect region-
speciﬁc tissue expression; however, it is also important to consider
methodological differences in this case. While the three papers
documenting down-regulation of this miRNA utilized in situ
hybridization by microarrays to measure expression, Cogswell
et al. (2008) used real-time PCR. This method could introduce
additional bias, since it requires primer ampliﬁcation instead of
direct measurement; therefore the consensus of the three other
papers on miR-29a/b down-regulation may be more credible in
this instance.
miR-29 also has been shown to inhibit neuronal apoptosis
during development via inhibition of genes in the pro-apoptotic
BH3-only family, which would otherwise inhibit pro-survival pro-
teins in the BCL-2 family (Kole et al., 2011). If one of the primary
functions of miR-29 is inhibition of apoptosis, onemight expect to
observe down-regulation in AD associated with an increased rate
of neurodegeneration caused by members of the pro-apoptotic
BH3-only gene family inhibiting BCL-2 proteins. For the majority
of studies just mentioned, miR-29 was in fact down-regulated in
association with disease pathology as predicted by this hypothe-
sis. Most current evidence suggests that miR-29 down-regulation
is associated with AD pathology. The up-regulation observed by
Cogswell et al. (2008) may reﬂect measurement in the medial
frontal gyrus, a region which was not included in other studies.
In cancer, miR-29 appears to interact directly with the BCL-2
family pro-survival proteins. It was down-regulated in malignant
cholangiocarcinoma cells with corresponding up-regulation of
anti-apoptotic myeloid cell leukemia sequence 1 (MCL-1, a mem-
ber of the BCL-2 anti-apoptotic family). Transfection of miR-29
decreased MCL-1 levels and increased sensitivity to drug-induced
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cytotoxicity (Mott et al., 2007). Supporting the validity of these
results and suggesting that this function may be common in can-
cer, miR-29 was observed to be down-regulated in melanoma,
mantle cell lymphoma, acute myelogenous leukemia (AML), hep-
atocellular carcinoma (HCC), cervical cancer, endometrial serous
adenocarcinoma, and non-small cell lung cancer (NSCLC), and
transfection of miR-29 was correlated with decreased tumori-
genicity (Fabbri et al., 2007; Garzon et al., 2009b; Hiroki et al.,
2010; Xiong et al., 2010; Zhao et al., 2010; Li et al., 2011d; Nguyen
et al., 2011). In AML, miR-29 expression is negatively correlated
with MCL-1 mRNA, while in HCC BCL-2 and MCL-1 were both
direct targets of miR-29; both of these ﬁndings support the the-
ory that miR-29 functions as a tumor suppressor in cancer by
promoting apoptosis (Garzon et al., 2009b; Xiong et al., 2010).
In addition to this apoptotic pathway, previous cancer research
also contains information linking miR-29 to other pathways. In
mantle cell lymphoma, miR-29 was shown to regulate cyclin-
dependent kinase 6 (CDK6) mRNA to inﬂuence cell division;
down-regulation of miR-29 was correlated with increased CDK6
and decreased survival (Zhao et al., 2010). This is supported by
research in cervical cancer, which indicated that miR-29 level
was negatively correlated with CDK6; addition of miR-29 to
human papillomavirus-infected cells was shown to retard cell
cycle progression and increase the frequency of apoptosis (Li et al.,
2011d). In cholangiocarcinoma cells miR-29 was transcriptionally
repressed by NF-κB protein, a key molecule in the inﬂammatory
pathway, as well as c-Myc and hedgehog proteins, implicating this
miRNA in proliferation down-regulation (Pikarsky et al., 2004;
Mott et al., 2007). In HCC, miR-29 was found to down-regulate
matrix metalloproteinase-2 (MMP2) expression, leading to anti-
angiogenesis via subsequent suppression of kinase insert domain
receptor (KDR, also called VEGFR2) signaling, as well as anti-
invasion effects (Fang et al., 2011). Supporting this, in CRC,
apolipoprotein BmRNAediting enzyme catalytic polypeptide-like
3G (APOBEC3G) promotes metastasis via inhibition of miR-29
and subsequent up-regulation of MMP2 (Ding et al., 2011). In
HCC, miR-29 was also implicated in up-regulation of the long
non-coding RNA maternally expressed gene 3 (MEG3), accom-
panied by inhibited anchorage-dependent and -independent cell
growth and increased apoptosis (Braconi et al., 2011). Finally,
miR-29 has been associated with transcriptional regulation in
cancer via regulation of DNA methylation genes. In melanoma,
miR-29 expression was inversely correlated with protein levels of
DNAmethyltransferases DNMT3A and DNMT3B,which affected
overall survival (Nguyen et al., 2011); miR-29 expression was
also negatively correlated with DNMT3A and B in lung cancer,
and transfection of miR-29 restored normal methylation patterns
and expression of various tumor suppressor genes, as well as
inhibiting tumorigenicity in vitro and in vivo (Fabbri et al., 2007).
From this evidence, miR-29 appears to act as a tumor suppres-
sor within a large variety of pathways involved in cancer including
apoptosis, tumorigenicity, cell cycle regulation, proliferation, inva-
sion, metastasis, angiogenesis, inﬂammation, and transcriptional
regulation.
This analysis of miR-29 implicates involvement in a variety
of pathways in cancer, only one of which has been observed in
AD. In addition to its activity in the amyloid pathway in AD,
down-regulation of miR-29 may allow BH3-only family proteins
to inhibit BCL-2 family proteins, leading to apoptosis,while in can-
cer action of BH3-only family proteins must be blocked somehow,
allowing BCL-2 family proteins to promote survival since miR-
29 is also down-regulated. The additional interactions of miR-29
in cancer should also be investigated in AD; for example, NF-κB,
which is known to be up-regulated in AD, was shown to target
miR-29 in cholangiocarcinoma, but to date has not been shown to
target this miRNA inAD (Lukiw et al., 2008). Given the ﬁndings in
cancer, it would be useful to determine whether miR-29 regulates
DNA methyltransferases CDK6 and MMP2 in brain, and, if so,
whether these interactions inﬂuence AD pathology.
miR-101
Previous studies have demonstrated down-regulation of miR-
101 in the temporal and parietal cortex (Hebert et al., 2008;
Nunez-Iglesias et al., 2010). Subsequently, miR-101 was shown to
down-regulate APP; additionally, lentiviral-mediated overexpres-
sion of miR-101 was observed to reduce ﬁbrillar Aβ and another
know target, cytochrome c oxidase subunit II (COX-2), in hip-
pocampal neurons (Vilardo et al., 2010). Another study replicated
miR-101 down-regulation of APP, and also demonstrated that
miR-101 is highly expressed in neural cells compared to HeLa and
neuroblastoma cells (Long and Lahiri, 2011). These studies indi-
cate that miR-101 down-regulation results in increased Aβ and
COX-2, which has previously been shown to induce the innate
immune complement component C1qB, and has been associated
with inﬂammation (Seibert et al., 1994; Spielman et al., 2002). Fur-
ther, COX-2 is elevated in hippocampal tissue in AD cases, and is
correlated with amyloid plaque density (Ho et al., 1999). miR-101
therefore may play an important regulatory role in the amyloid,
inﬂammatory, and immune pathways, and down-regulation may
exacerbate disease pathology.
There is an extensive body of research on the multiple roles
of miR-101 in cancer. miR-101 is consistently down-regulated
in many cancers including acute lymphoblastic leukemia, HCC,
glioblastoma, lung, gastric, colon, renal, prostate, ovarian, blad-
der, and pancreatic cancer (Varambally et al., 2008; Strillacci et al.,
2009; Su et al., 2009; Hiroki et al., 2010; Smits et al., 2010; Wang
et al., 2010a; Banerjee et al., 2011; Hao et al., 2011; Kottakis et al.,
2011; Semaan et al., 2011;Thu et al., 2011; Zhang et al., 2011a;
Au et al., 2012; Bao et al., 2012; Carvalho et al., 2012; Liu et al.,
2012c; Luo et al., 2012). Down-regulation was associated with
many oncogenic characteristics including increased proliferation,
invasion, advanced tumor stage, and decreased survival; cellu-
lar transfection with miR-101 resulted in increased apoptosis and
inhibited proliferation, invasion, and angiogenesis, via inhibition
of primary target molecules such as the histone methyltransferase
enhancer of zeste homolog 2 (EZH2), COX-2, and MCL-1. EZH2
is a transcriptional regulatory molecule which can potentially reg-
ulate many different pathways, greatly increasing the impact of
miR-101 activity or loss. Redundancy is reﬂected in miR-29 and
miR-101 regulation of the anti-apoptotic MCL-1, indicating that
this is an important pathway in cancer and highlighting the poten-
tial for future AD research, given that molecules involved in cell
survival could play an important role in neurodegeneration. As
discussed earlier, COX-2 has been implicated in inﬂammatory
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and immune pathways; this functional interaction is seen in both
AD and cancer, reﬂecting the importance of these pathways in
both diseases and indicating that miR-101 may be a key negative
regulator of both diseases.
miR-107
miR-107 down-regulation has been reported in AD and has been
related to amyloid plaque density, neuritic plaque counts, and
neuroﬁbrillary tangle counts in adjacent tissue (Nelson andWang,
2010;Wang et al., 2011). Additionally,miR-107has been correlated
withBACE1mRNA level, andBACE1has been shown tohavemiR-
107 sequence target sites. Thus in AD,miR-107 may be a regulator
of BACE1 activity and consequently affect APP cleavage (Wang
et al., 2008a; Nelson and Wang, 2010). These results support the
role of miR-107 down-regulation in AD and suggest a mechanism
related to plaque burden.
Regulation in cancer is more of a mixed picture; there is con-
ﬂicting evidence for miR-107 regulation in prostate cancer and
gastric cancer, indicating that more research on this topic is
needed. In prostate cancer, there is evidence that down-regulation
of miR-107 is correlated with up-regulation of the mitogen and
growth factor granulin (GRN); other members of this miRNA
family have also been shown to display this pattern of down-
regulation with associated up-regulation of GRN in 11 different
types of cancer (Wang et al., 2010b). In contrast, a signiﬁcantly
higher level of miR-107 was found in the urine of men with
prostate cancer, suggesting that this miRNA may be up-regulated
(Bryant et al., 2012). Additional research is needed to resolve this
apparent discrepancy. In gastric cancer, there is also conﬂicting
evidence for regulation of miR-107; expression was signiﬁcantly
elevated in gastric tumor tissue compared to normal tissue, was
associated with depth of invasion, lymph node metastasis, and
stage, decreased overall survival and disease-free survival, and
was inversely correlated with DICER1 mRNA, indicating possi-
ble involvement in translational regulation (Li et al., 2011c; Inoue
et al., 2012). However, miR-107 was also observed to be silenced
in gastric cancer cells, and transfection of miR-107 was corre-
latedwith down-regulation of CDK6mRNAand protein, cell cycle
arrest, and decreased proliferation and invasion (Feng et al., 2012).
At this time, more research is needed to clarify the roles of miR-
107 in prostate and gastric cancer, and whether it is ultimately
oncogenic or tumor suppressive.
miR-107 has also been shown to be up-regulated in breast
cancer, and down-regulated or silenced in HNSCC, colon can-
cer, and pancreatic cancer. In breast cancer, miR-107 was found
to be up-regulated, was shown to silence the tumor suppres-
sive miRNA let-7, and was associated with increased tumorigenic
potential and metastases in mice (Chen et al., 2011). In HNSCC,
low expression of miR-107 was correlated with increased protein
kinase Cδ (PKCδ), and miR-107 inhibited proliferation, DNA
replication, colony formation, and invasion (Datta et al., 2011).
miR-107 has been implicated in angiogenesis in colon cancer; the
tumor suppressive transcription factor P53 canmediate transcrip-
tion of miR-107, and forced expression of miR-107 suppresses
expression of hypoxia inducible factor-1beta (HIF-1b), suppress-
ing angiogenesis, tumor growth, and vascular endothelial growth
factor (VEGF) expression (Yamakuchi et al., 2010). Finally, in
pancreatic cancer cell lines, miR-107 was reported to be epige-
netically silenced, and re-expression by a demethylating agent in
tumor cell lines inhibited CDK6 and decreased growth in vitro,
indicating that miR-107 is also involved in a cell cycle regulatory
pathway (Lee et al., 2009). It is possible that the regulation of let-
7 by miR-107 in breast cancer overrides other interactions since
let-7 has been shown to affect a large number of targets, and that
this level of regulation may be blocked in other cancers, allowing
othermiR-107 interactions to take precedence and produce tumor
suppressive effects.
A number of different pathways appear to be regulated bymiR-
107 in cancer includingproliferation, invasionmetastasis, cell cycle
regulation, additive translational regulation (mediated by let-7),
and angiogenesis. More information on the potential interaction
of miR-107 with DICER1, CDK6, HIF-1b, and GRN could further
elucidate the molecular pathways involved in AD, as well as the
regulatory process of disease initiation and progression. Progran-
ulin (GRN) is a particularly interesting association, given that it
has been found to cause one form of frontotemporal lobar degen-
eration (van Swieten and Heutink, 2008). The altered expression
patterns for various types of cancer and AD may indicate that
there is another level of regulation that differs across tissues. This
in turn may be modulated by other miRNAs, which could alter
the methylation status of miR-107 via interaction with histone
methyltransferases.
miR-125b
Small increases inmiR-125b have been observed in the hippocam-
pal region of AD brains post-mortem. Because synapsin II mRNA
has been identiﬁed as a target for this miRNA, it has been pos-
tulated that it may be responsible for synapsin protein deﬁcits
observed in thebrains of patientswithAD(Perdahl et al., 1984;Qin
et al., 2004; Krek et al., 2005; John et al., 2006; Lukiw, 2007, 2012).
miR-125b has been shown to be signiﬁcantly up-regulated in the
temporal lobe neocortex of AD patients (Sethi and Lukiw, 2009;
Lukiw et al., 2012). miR-125b was also found to be up-regulated in
the hippocampus, medial frontal gyrus, and cerebellum (Cogswell
et al., 2008). Further,miR-125b was positively correlated with gray
matter neuroﬁbrillary tangles in post-mortemAD patients (Wang
et al., 2011). Finally, in cultured human neuronal glial cells, miR-
125b has been shown to be up-regulated by NF-κB in response
to IL-1β and Aβ42-peptide-induced stress; in this model, miR-
125b was also shown to target the mRNA of complement factor-H
(CFH), known to be an important suppressor of immune and
inﬂammatory pathways in the brain, and lead to decreased expres-
sion (Lukiw et al., 2008; Lukiw and Alexandrov, 2012). From these
reports, miR-125b is implicated in neuropathological change, and
appears to function in the inﬂammatory and oxidative stress NF-
κB pathways, innate immunity via CFH, and cellular transport via
synapsin.
In cancer, miR-125b appears to function mostly as a tumor
suppressor. The majority of research to date has been done in
HCC;down-regulationofmiR-125bhas been linked to tumorpro-
gression and metastasis, tumorigenicity, proliferation, migration,
invasion, angiogenesis, and cell cycle de-regulation in HCC or
HCC cell lines (Liang et al., 2010; Alpini et al., 2011; Au et al.,
2012). In this disease, miR-125b was shown to be silenced by
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methylation; miR-125b was also shown to decrease angiogenesis
via regulation of placenta growth factor (PIGF), a member of the
VEGF family, as well asMMP2 andMMP9, whichmay be involved
in miR-125b effects on invasion (Alpini et al., 2011). Investiga-
tion of the effects of miR-125b on angiogenesis in more depth
in epithelial cells reveal contradictory evidence that VEGF can
induce miR-125b, which in turn inhibits translation of vascular
endothelial cadherin (VE-cadherin) and in vitro tube formation;
overexpression of miR-125bwas shown to result in non-functional
blood vessel formation, indicating that miR-125b could pro-
mote angiogenesis (Muramatsu et al., 2012). It is possible that
this contradiction is caused by the model; miR-125b may act
through different pathways in cancerous tissue. miR-125b was
also shown to up-regulate cyclin-dependent kinase inhibitor 1
(CDKN1A) expression, which arrested cell cycle transition and
silenced LIN28B; these effects were linked to inhibited growth,
migration, and invasion (Liang et al., 2010). The histone methyl-
transferase EZH2 was shown to down-regulate miR-125b in HCC,
resulting in progression andmetastasis (Au et al., 2012). In bladder
cancer, miR-125b also appears to function as a tumor suppressor;
miR-125b inhibits E2F3, which is involved in the G1/S phase cell
transition, and transfection of miR-125b in bladder cancer cell
lines decreased E2F3 protein and cyclin A2, depressing colony
formation in vitro and tumor development in mice (Huang et al.,
2011). Contrary to these results, a study in glioma found thatmiR-
125bpromotes glioma cell proliferation and inhibits drug-induced
apoptosis, indicating that it may play an oncogenic role in this
particular disease; the authors further found that miR-125b may
target and down-regulate apoptosis-related protein BCL-2 modi-
fying factor, and apoptotic activator (BMF; Xia et al., 2009). Aside
from glioma, miR-125b seems to play a tumor suppressive role
in a variety of molecular pathways, though miR-125b should be
investigated to determine whether this is also true in other cancer
types.
Given the largely tumor suppressive function of miR-125b,
which inhibits growth and is down-regulated in cancer, we would
expectmiR-125b to be up-regulated inADwith resulting neurode-
generation, which has been observed as noted above. However, the
speciﬁc interactions of miR-125b with molecules in a large variety
of pathways have not been investigated in AD; research to deter-
minewhethermiR-125bdirectly interactswith themolecules listed
above including angiogenic VEGF, cell cycle regulatory E2F3, and
apoptotic activator BMF could shed more light on the molecular
mechanisms involved in AD pathology and further elucidate the
pathways involved in this disease. Interestingly, the role of miR-
125b in innate immunity does not appear to have been speciﬁcally
investigated in cancer at this point; this could be an important
factor in cancer etiology which should be further investigated
as well.
miR-146
Similarly to miR-125b, miR-146a was found to be signiﬁcantly
up-regulated in the temporal cortices of patients with AD (Sethi
and Lukiw, 2009; Lukiw et al., 2012). It was shown to function
similarly to miR-125b in the AD inﬂammatory and oxidative
stress pathways, as it was shown to be up-regulated by NF-κB in
response to IL-1β and Aβ42 or oxidative stress in cultured human
neuronal glial cells, and to decrease expression of CFH (Lukiw
et al., 2008; Cui et al., 2010; Lukiw and Alexandrov, 2012). Consis-
tent with these results, miR-146a was observed to be up-regulated
in AD neocortices, and in IL-1β and Aβ42 stressed human
astroglial cells; in the astroglial model miR-146a down-regulates
the Toll-like receptor signaling molecule IL-1 receptor-associated
kinase 1 (IRAK1) in tandem with IRAK2 up-regulation by NF-
κB to promote the innate immune and inﬂammatory responses
(Cui et al., 2010). Interestingly, unlike miR-146a, miR-146b was
down-regulated in both the hippocampus and medial frontal
gyrus in individuals with AD; the researchers postulate that
down-regulation of miR-146b relieves inhibition of IRAK1 and
another TLR signaling molecule, TNF receptor-associated fac-
tor 6 (TRAF6), triggering the innate immunity pathway which
contributes to the activation of microglia and neurodegenera-
tion (Cogswell et al., 2008). More work is needed to clarify these
apparently contradictory roles of miR-146a/b in AD.
Up-regulation of miR-146a was observed in anaplastic thy-
roid carcinoma (ATC) and cervical cancer, while down-regulation
was observed for miR-146a in pancreatic cancer, and miR-146a
and b in prostate and breast cancer, indicating that these miR-
NAs may play a variety of oncogenic or tumor suppressive roles
in different cancers (Bhaumik et al., 2008; Lin et al., 2008; Wang
et al., 2008b; Hurst et al., 2009; Li et al., 2010; Paciﬁco et al., 2010;
Man et al., 2011). mir-146a has been characterized as oncogenic
in ATC, activated by the inﬂammatory molecule NF-κB; inhibi-
tion of miR-146a decreased oncogenic potential in ATC-derived
cells and increased susceptibility to chemotherapy-induced cyto-
toxicity (Paciﬁco et al., 2010). Additional oncogenic function was
observed in cervical cancer, wherein miR-146a was signiﬁcantly
up-regulated in cervical cancer and was tied to cellular prolif-
eration (Wang et al., 2008b). In contrast, miR-146a and b have
also been shown to have a variety of tumor suppressive functions
in breast, prostate, and pancreatic cancer. Functional interaction
research in breast cancer indicates that breast cancer metastasis
suppressor 1 (BRMS1) up-regulates miR-146a and b; expression
of eithermiRNA resulted in down-regulation of epidermal growth
factor receptor (EGFR) and reduced invasion, migration, and
metastasis (Hurst et al., 2009). Also in breast cancer, miR-146a
and miR-146b expression suppressed IRAK1 and TRAF6, which
was reported to impair NF-κB activity, resulting in reduced inva-
sion and migration (Bhaumik et al., 2008). This negative feedback
loop was also observed previously in an acute monocytic leukemia
cell line, indicating that miR-146a and b appear to be involved
in negatively as well as positively regulating oxidative, immune,
and inﬂammatory responses (Taganov et al., 2006). Transfectionof
miR-146a in prostate cancer cell lines led to signiﬁcantly reduced
expression of ROCK1 and reduced proliferation, invasion, and
metastasis; down-regulation of either miR-146a or b in prostate
cancer was also linked to focal basal cell layer disruptions, which
have been correlated with invasion (Lin et al., 2008; Man et al.,
2011). Similarly, re-expression of miR-146a induced by isoﬂavone
in pancreatic cancer was also correlated with reduced invasion
and down-regulation of IRAK1 and EGFR, indicating that this
molecular pathway is involved in multiple cancers (Li et al., 2010).
Finally, genetic studies have linked polymorphisms inmiR-146a to
increased risk of gastric cancer, breast cancer, and papillary thyroid
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carcinoma, while meta-analyses have also linked risk to more gen-
eralized cancer susceptibility (Tian et al., 2010; Zeng et al., 2010;
Qiu et al., 2011; Lian et al., 2012;Wang et al., 2012a). These various
disparate pieces of evidence indicate that miR-146a plays a variety
of roles in different cancer types, though there seems to be a com-
monality to the interactions observed for the tumor suppressive
roles miR-146a plays in prostate, pancreatic, and breast cancer.
More research would be helpful in clarifying the mediatory mech-
anisms which determine whether miR-146a is tumor suppressive
or oncogenic.
Comparing the evidence formiR-146a function inAD and can-
cer, there seems to bemore overlap than for themiRNAspreviously
reviewed, though results from cancer may still inform additional
interactions in AD. For instance, an investigation of miR-146a
regulation of EGFR in AD may tie this miRNA to a proliferative
pathway; logically, if these molecules are negatively regulated and
miR-146a is up-regulated in AD, one would expect a decrease in
EGFR, with possible subsequent neurodegenerative effects. For
example, in rodents with traumatic brain injury, treatment with
epidermal growth factor reduced hippocampal neuronal cell loss
and improved cognitive function (Biessels et al., 2006). Interest-
ingly, modulation of the inﬂammatory/innate immune pathway
by miR-146a appears to be play a large role common to both dis-
eases. The evidence thatmiR-146a andb inhibit IRAK1andTRAF6
in breast cancer may contradict the hypothesis of Cogswell et al.
(2008) that miR-146b relieves inhibition of thesemolecules in AD,
though a functional study of this interaction, as well as the sub-
sequent NF-κB modulation, would be required for clariﬁcation.
Finally, it is important that future studies make an effort to clarify
the role of miR-146b in cancer, as many results to date have con-
cernedmiR-146a; since there seems to be functional overlap based
on current research, it would be interesting to investigate further
whether these two miRNAs may be differentially regulated in AD.
miR-153
This miRNA has not been studied as extensively as others men-
tioned in this review, but is discussed because it has been very
recently implicated in regulation of APP. Long et al. (2012) found
that delivery of miR-153 in human fetal brain cultures reduced
expression of APP, as well as an APP paralog, APLP2, via direct
interactionwith a target site on theAPP3′UTR,while inhibition of
miR-153 resulted in increased expression of APP; supporting this,
decreased miR-153 and increased APP were observed in a subset
of AD patients withmoderate pathology (Long et al., 2012). Given
this important functional evidence for miR-153 interaction in the
amyloid pathway, it seems important to review current research of
this miRNA in cancer to see if we can extrapolate any further roles
or further elucidate molecular function for miR-153.
As with the results for AD, a review of cancer research does
not yield much information on miR-153; however, the few studies
published may shed additional light of the function of this regu-
latory molecule. In ovarian cancer, miR-153 was down-regulated,
and expression was different for four histopathological types of
ovarian cancer; the researchers subsequently found that miR-
153 was signiﬁcantly correlated with tumor grade and clinical
stage (Kim et al., 2010). A key study found that miR-153 is
down-regulated in glioblastoma, with re-expression in cell lines
associated with decreased proliferation and increased apoptosis;
the researchers further demonstrated that miR-153 directly inhib-
ited anti-apoptosis molecules BCL-2 and MCL-1 (Xu et al., 2010).
An additional study in the same model found that miR-153 also
inhibits the insulin receptor substrate 2 (IRS2), further implicating
it in growth regulation (Xu et al., 2011). These studies characterize
the tumor suppressive role of miR-153, as well as speciﬁc inter-
actions which appear to mediate this function. Interestingly, the
same endometrial cancer study mentioned previously for miR-9
also found that miR-153 has similar oncogenic properties, appear-
ing to down-regulate FOXO1 and apoptosis (Myatt et al., 2010).
This oncogenic function seems to contradict other tumor suppres-
sive functions listed above and indicates that this miRNA would
beneﬁt from more intense scrutiny.
Mediation of BCL-2 and MCL-1 by miR-153 indicates that it
mayhaveoverlapping functionalitywithmiR-29 and101; however,
the majority of evidence indicates that these miRNAs are down-
regulated in AD, whereas if they were inhibiting anti-apoptotic
molecules, wewould expect them to be up-regulated inAD leading
to neurodegeneration. Additional research is needed to determine
if miR-153 can also inhibit anti-apoptosis molecules in the brain,
as well as why this interaction would be suppressed in a neurode-
generative disease like AD. Interestingly, if miR-153 does in fact
interact with IRS2, that would tie this miRNA to the insulin reg-
ulatory pathway; in addition to the known association of diabetes
with increased dementia risk, there is some evidence that insulin
may be directly involved in AD, so this association should be a
focus of further investigation (Watson and Craft, 2003; Biessels
and Kappelle, 2005; Craft, 2007; Whitmer, 2007).
miR-195
There is comparatively little evidence for the involvement of
miR-195 in AD; however, miR-195 has been shown to directly
target the 3′ UTR ofBACE1, and to decrease protein expression
in mouse neuroblastoma cells, with a corresponding drop in Aβ
levels (Zhu et al., 2012a). Additionally, miR-195 was decreased
in the cerebral spinal ﬂuid (CSF) of AD patients compared with
controls (Cogswell et al., 2008), while another group found that
miR-195 was down-regulated and was negatively correlated with
diffuse amyloid plaques in the gray matter of post-mortem AD
patients (Wang et al., 2011). Given these limited but interest-
ing results, it seems important to review the roles of miR-195
in cancer to see if additional information about miR-195 in the
brain can be extrapolated for further investigation. Since down-
regulation could theoretically be tied to increased amyloid beta
levels, establishing expression patterns of this miRNA in AD brain
tissue should be a research priority, along with more functional
investigation.
Importantly, miR-195 has been extensively studied in cancer,
with current research indicating that it plays tumor suppressive
or oncogenic roles in different cancer types. Down-regulation was
observed in a number of different cancer types, and was associated
with poorer overall survival, increased metastasis incidence, and
higher tumor stage; however, up-regulation was also observed in
several cancer types (Zanette et al., 2007; Flavin et al., 2009; Guled
et al., 2009; Soon et al., 2009; Xu et al., 2009; Liu et al., 2010; Moser
and Fritzler, 2010; Ozata et al., 2011; Guo et al., 2012; Lin et al.,
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2012; Wang et al., 2012b; Zhang et al., 2012). In breast cancer and
glioma, conﬂicting studies indicate that more research is needed
to determine the impact of this miRNA (Heneghan et al., 2010a,b;
Ujifuku et al., 2010; Lakomy et al., 2011; Li et al., 2011a). Research
in the tumor suppressive functions of miR-195 has shown that it
interacts with a number of molecules involved in cell cycle regula-
tion, as well as metabolic and anti-apoptotic molecules. miR-195
was shown to inhibit cyclin D1 in HCC and breast cancer (Xu
et al., 2009; Li et al., 2011a), CCND3 in glioblastoma (Zhang et al.,
2012), CDK4 in bladder cancer (Lin et al., 2012), CDK6 in HCC
(Xu et al., 2009), E2F3 in HCC and glioblastoma (Xu et al., 2009;
Zhang et al., 2012), BCL-2 in breast and colorectal cancer (Liu
et al., 2010; Singh and Saini, 2012), RAF1 in breast cancer (Li et al.,
2011a), and GLUT3 in bladder cancer (Fei et al., 2012). The role
of miR-195 in suppression of anti-apoptotic BCL-2 lends support
to the evidence that miR-195 is down-regulated in breast cancer,
promoting cell survival. Unsurprisingly given these genes’ known
roles in cell cycle regulation,metabolism, and anti-apoptosis, inhi-
bition via miR-195 was variously associated with cell cycle arrest,
decreased proliferation, reduced invasion, increased apoptosis,
and reduced colony formation and tumor formation. Interestingly,
given that the only clinical measure associated with up-regulation
at this point is increased resistance to temozolomide (Ujifuku et al.,
2010), it is possible that the tumor suppressive functions of miR-
195 early in cancer development are overridden by oncogenic
interactions favoring survival in the context of drug resistance;
further investigation of this is merited in cancers associated with
miR-195 up-regulation as listed above. The dearth of functional
and clinical investigation of miR-195 up-regulation, as well as
the contradiction between research indicating that it may be up
or down-regulated in breast cancer and glioblastoma, should
be addressed to further clarify the mechanisms of miR-195 in
cancer.
From the current literature detailing the tumor suppressive role
of miR-195 in various cancers, it is possible to hypothesize that
this miRNA has functional overlap with miR-29 and miR-153,
both of which have been shown to interact with BCL-2, which
would lead to the additional hypothesis that miR-195 is simi-
larly down-regulated in AD. This is a logical expectation given
the functional evidence that decreases in miR-195 could be tied
to increased amyloid beta and decreased levels were observed in
CSF and gray matter, however, it requires further investigation.
Researching these premises might also point to the possibility
that all three miRNAs are regulated via a common mechanism
in AD given their apparent redundancy. As suggested earlier, fur-
ther investigation in AD of the functional interactions ascribed to
thismiRNA in cancermight help elucidate additionalmechanisms
by which it inﬂuences AD pathology. Given the evidence in can-
cer, it is possible that this miRNA is also important in proliferative
pathways in the brain.
PATHWAYS
The overall involvement of miRNAs under consideration in this
review in speciﬁc biological pathways is summarized in Figure 4,
including oncogenic and tumor suppressive functions in can-
cer and amyloid-speciﬁc mechanisms. The amyloid pathway has
FIGURE 4 | Summary of miRNA pathway relationships in cancer and AD. Major pathways are listed; dots indicate evidence that a speciﬁc miRNA is
involved in a particular pathway. Red indicates evidence from cancer research, blue from AD research, and purple from both cancer and AD.
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clearly been a focus of AD research to date. We have reviewed evi-
dence that multiple miRNAs regulate expression of molecules in
this pathway; mir-9, -29a/b, -107, and -195 have been predicted or
shown to target, or negatively correlated with, BACE1 mRNA or
protein levels, suggesting that these miRNAs may have functional
overlap or redundancy, while miR-101 and -153 have been shown
to inhibit APP protein directly (Figure 2).
In addition, miR-9, 125b, and 146a are up-regulated by the
inﬂammatory and oxidative stress responses, suggesting that the
amyloid pathway may have wide-reaching regulatory impact via
miRNA.
The inﬂammatory and innate immune pathways have been
extensively investigated in both cancer and AD. miRNAs appear
to be important in these pathways in both diseases and may func-
tion using some of the same mechanisms (Figure 5). Regulation
involving the major inﬂammatory and oxidative stress transcrip-
tion factor NF-κB is a common theme observed for many of the
miRNAs reviewed here. This molecule is a key signaling molecule
in AD as it appears to tie together the amyloid, inﬂammatory,
oxidative stress, and innate immunity pathways, but it has also
been shown to play an important role in cancer. As discussed
earlier in this review, in cancer, miR-9 down-regulates NF-κB and
NF-κB appears to directly down-regulatemiR-29a and up-regulate
miR-146a, while inAD,NF-κB appears to up-regulatemiR-9,miR-
125b, and miR-146a. miR-125b and -146a regulate several other
molecules in the NF-κB pathway and indirectly modulate NF-
κB; miR-146a has been shown to down-regulate TLR signaling
molecules IRAK1 andTRAF6 in cancer, with a corresponding drop
in NF-κB level. Interestingly, miR-146a was also shown to down-
regulate IRAK1 in AD, but did not affect TRAF6 in the Aβ42 and
IL-1β-stressed human cultured astroglial cell model (Cui et al.,
2010). This process has been postulated to result in “ﬁne-tuning”
of these pathways, and may be aided by miR-9 down-regulation
of NF-κB, though this remains to be veriﬁed in AD. Given the
similar expression and activation of miR-125b compared with
miR-146a, it would also be interesting to investigate whether this
miRNAmay also regulate downstream TLR signaling via a similar
mechanism.
Additionally, in AD, mir-125b and -146a have been shown to
regulate CFH, which normally represses the cerebral inﬂamma-
tion response. CFH has also been shown to play an important
regulatory role in the complement cascade, which is a major
component of innate immunity. Dysregulation has also been
observed in Down’s syndrome, which shares some neuropatho-
logical characteristics of AD (Li et al., 2012). Interestingly, CFH
polymorphisms have been previously associated with increased
risk of AD in apolipoprotein E ε4 carriers, indicating that this
miRNA regulatory mechanism could be an important factor in
pathology, and should be further investigated (Zetterberg et al.,
2008). Based on the evidence in cancer research, an investigation
of the interaction of miR-9 and -29b with NF-κB in AD and pos-
sible downstream targets in these pathways may further clarify the
molecular mechanisms involved. mir-101 regulation of COX-2,
which has been associated with innate immunity and inﬂamma-
tion, adds complexity to this regulatory pathway.We conclude that
the innate immune, oxidative stress, and inﬂammatory pathways
regulated by miRNAs are important in cancer and AD, and utilize
some overlapping functional mechanisms; further research into
each area based on previous research presented here could help to
advance knowledge in both disease areas.
To date, most miRNA research on functional molecular inter-
actions in AD has focused on the amyloid and inﬂammation
pathways since these have been directly implicated in neuropathol-
ogy. However, a number of other pathways have been postulated
or demonstrated to play a role in AD including proliferation
and angiogenesis. Metastasis and invasion, key topics in can-
cer research, have been shown to be effectively regulated by
miRNAs.
FIGURE 5 | MicroRNA involvement in the inflammation, innate
immunity, and oxidative stress pathways in AD and cancer.This pathway
has been validated by several studies in AD; however, additional evidence
from cancer research points to more molecules which may be involved. Blue
lines indicate interactions and effects found in AD research, orange lines
indicate interactions and effects found in cancer research, and black lines
indicate ﬁndings common to both diseases. Dashed lines indicate
downstream effects.
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Given that some of the underlying functions of extracellular
matrix degradation, stemness, and differentiation could affect
neurophysiology and be involved in AD, miRNA regulation of
matrix metalloproteinases, cyclin-dependent kinases, and cyclins,
all of which have been observed in cancer, should also be investi-
gated in AD. Proliferative molecules including GLUT3 and IRS2,
which are speciﬁcally involved in cell metabolism and appear to
be differentially regulated by miRNAs in cancer, could also con-
tribute to risk for AD and increased rates of neurodegeneration
via impaired metabolism. Pro-survival genes such as BCL-2 and
MCL-1 have been observed to be redundantly regulated by multi-
ple miRNAs in cancer; inappropriate silencing of these molecules
by miRNAs in AD could exacerbate neurodegeneration. Cell cycle
regulatory molecules such as cyclin-dependent kinases, cyclins,
and E2F3, are shown to be targets of several of the miRNAs dis-
cussed, indicating that these miRNAs can inhibit the cell cycle
(Figure 6).
Amyloid beta appears to up-regulate angiogenesis, suggesting
that this may be an important area for future miRNA research
in AD (Cameron et al., 2012). As discussed earlier, various miR-
NAs have been shown to play important roles in angiogenesis
in cancer. miR-29 down-regulates MMP2, indirectly reducing
VEGFR2 signaling and angiogenesis, miR-107 reduces HIF-1b,
with subsequently reduced angiogenesis, tumor growth, and
VEGF expression, and miR-125b was shown to inhibit PIGF and
VE-cadherin in different cell lines, inhibiting angiogenesis.
Interestingly, all instances of angiogenic regulation observed
here were tumor suppressive, indicating a degree of func-
tional redundancy, but one of the four miRNAs implicated was
up-regulated in AD. miR-125b may be differentially expressed
because it has been shown to be up-regulated by amyloid beta.
TRAF6, the innate immune molecule down-regulated by miR-
146a in breast cancer, has also been shown to negatively regulate
VEGF in epithelial cells, leading to the question of whether the
miR-146a regulatory pathway may result in increased VEGF sig-
naling and angiogenesis (Bruneau et al., 2012). This pathway,
which has been implicated in AD, should be further investi-
gated for miRNA regulation to elucidate function and disease risk
factors.
Transcriptional and translational regulation of miRNAs and
target genes is also a key process in both diseases, with multiple
hierarchical levels of control and feedback mechanisms playing
important roles in effect size and speciﬁcity. While miRNAs are
inherently involved in translational regulation via the RISC silenc-
ing complex (Figure 1), several miRNAs in this review have may
affect translational regulation at a higher level; both miR-9 and
-107 have been shown to inhibit DICER1, and miR-107 has been
shown to inhibit another miRNA, let-7. Interestingly, miR-29 and
-101 have been implicated in transcription control via inhibi-
tion of methyltransferases. An investigation of these properties
could elucidate additional functions of these miRNAs and provide
information on this important regulatory pathway in AD.
CONCLUSION
MicroRNAs are clearly a relevant topic for both cancer and neu-
rodegenerative disease. Many of the miRNAs discussed in this
review have differential expression in AD and cancer, suggesting
that they play multiple regulatory roles in pathways active across
both cancer and AD (Table 1). While miRNA has been actively
researched in cancer for a number of years, this is a relatively
new area for research in AD and other neurodegenerative dis-
eases. From a review of the literature on miRNAs in AD, much
work remains to be accomplished to elucidate all roles of miRNAs
in pathological pathways. Reviewing a number of miRNAs with
functional evidence of involvement in AD indicates that other
than the amyloid pathway and inﬂammation, possible regulation
of other pathways by thesemolecules has been largely ignored. This
review of miRNA regulatory mechanisms in cancer and AD has
FIGURE 6 | Redundant miRNA mechanisms regulating proliferation
and survival pathways in cancer. Expression of transcription factors,
BCL-2 family genes and inhibitors, and cell cycle regulatory molecules is
redundantly regulated by miRNAs in cancer, prompting speculation
about possible regulatory roles of these miRNAs in a similar pathway
in AD.
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Table 1 | miRNA expression in cancer and AD.
miRNA Types of Cancer (see text for citations) Alzheimer’s disease affected tissue
Down-regulated Up-regulated Down-regulated Up-regulated
miR-9 Melanoma and HNSCC Glioma, GC, biliary, Hodgkin
lymphoma, CRC, BC, cervical
Hippocampus, medial frontal
gyrus, ATC
Hippocampus, TL
miR-29 Cholangiocarcinoma, melanoma, MCL,
AML, HCC, cervical, non-small cell lung
SMTG, parietal lobe cortex,
ATC
Medial frontal gyrus
miR-101 ALL, HCC, glioma, lung, GC, colon, renal,
PC, ovarian, bladder, pancreatic
Parietal lobe cortex, ATC
miR-107 GC, PC, HNSCC, colon, pancreatic GC, PC, BC SMTG (replicated)
miR-125b HCC, bladder Glioma TL, hippocampus, medial frontal
gyrus, cerebellum, HNG
miR-146a Anaplastic thyroid, cervical Pancreatic, PC, BC TL, HNG, human astroglial cells
miR-153 Ovarian, glioma Endometrial Frontal cortex
miR-195 BC, glioma, CRC, bladder, adrenocortical,
HCC, primary peritoneal
BC, glioma, astrocytoma,
CLL, malignant mesothelioma
CSF, SMTG
MiRNAs are signiﬁcantly differentially expressed, indicating different roles in disease.
HNSCC, head and neck squamous cell carcinoma; GC, gastric cancer; CRC, colorectal cancer; BC, breast cancer; ATC, anterior temporal cortex; TL, temporal lobe
neocortex; MCL, mantle cell lymphoma; AML, acute myelogenous leukemia; HCC, hepatocellular carcinoma; SMTG, superior and middle temporal gyri; ALL, acute
lymphoblastic leukemia; PC, prostate cancer; HNG, human neuronal-glial cells in culture; CLL, chronic lymphocytic leukemia.
covered a variety of important molecular mechanisms observed in
cancer that could potentially also contribute to pathology in AD.
Further investigation of these pathways and mechanisms appears
warranted and will hopefully be a focus of future research. Stud-
ies addressing other biological pathways such as proliferation and
angiogenesis would be important and help ﬁll the gaps in our
understanding of the regulatory mechanisms inﬂuencing this very
complex disease.
A comparison of research on miRNAs in cancer and AD high-
lighted areas which could beneﬁt from future research in both
diseases. Though the primary focus was on increasing knowledge
of AD from previous research in cancer; this case study also
demonstrates that a similar strategy could be useful in studying
other neurodegenerative diseases, which are starting to experience
increasing attention with regard to the roles of miRNAs in disease
pathophysiology.
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